Abstract:Objective: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy. Data sources: This review was based on a comprehensive search using online literature databases, including PubMed, Web of Science, and Google Scholar. Study selection: Literature search was based on the following keywords: Alzheimer's disease, tau protein, biomarker, cerebrospinal fluid (CSF), therapeutics, plasma, imaging, propagation, spreading, seeding, prion, conformational templating, and posttranslational modification. Relevant articles were carefully reviewed, with no exclusions applied to study design and publication type. Results: Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD. Although the Aβ hypothesis has dominated AD research for many years, clinical Aβ-targeting strategies have consistently failed to effectively treat AD or prevent AD onset. The research focus in AD has recently shifted to the role of tau in AD. In addition to phosphorylation, tau is acetylated and proteolytically cleaved, which also contribute to its physiological and pathological functions. Emerging evidence characterizing pathological tau propagation and spreading provides new avenues for research into the molecular and cellular mechanisms underlying AD pathogenesis. Techniques to detect tau at minute levels in CSF and blood have been developed, and improved tracers have facilitated tau imaging in the brain. These advances have potential to accurately determine tau levels at early diagnostic stages in AD. Given that tau is a potential therapeutic target, anti-tau immunotherapy may potentially be a viable treatment strategy in AD intervention. Conclusion: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.

Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer's disease

Proteostasis disruption and senescence in Alzheimer's disease pathways to neurodegeneration

Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies

Cellular senescence and neurodegeneration

The Mechanistic Link Between Tau-Driven Proteotoxic Stress and Cellular Senescence in Alzheimer's Disease

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development

Etiological Insights and Degradation Strategies

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Aging-Related Protein Alterations in the Brain

Molecular and Cellular Foundations of Aging of the Brain: Anti-aging Strategies in Alzheimer's Disease

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

Beyond amyloid and tau: rethinking Alzheimer's disease through less explored avenues

Unveiling the impact of Aging on BBB and Alzheimer's disease: Factors and Therapeutic implications

Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Inhibition of Tau by Phytocompounds and Extracts from Medicinal Plants

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy

Multiple Targets for the Management of Alzheimer’s Disease

The New Perspective of Alzheimer's Disease Research: Mechanism and Therapeutic Strategy of Neuronal Senescence

Exploring complexities of Alzheimer's disease: New insights into molecular and cellular mechanisms of neurodegeneration and targeted therapeutic interventions